We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 18, 2021

Different Carfilzomib-Based Treatment Regimens in Patients With Newly Diagnosed Multiple Myeloma

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Lancet Oncol 2021 Dec 01;22(12)1705-1720, F Gay, P Musto, D Rota-Scalabrini, L Bertamini, A Belotti, M Galli, M Offidani, E Zamagni, A Ledda, M Grasso, S Ballanti, A Spadano, M Cea, F Patriarca, M D'Agostino, A Capra, N Giuliani, P de Fabritiis, S Aquino, A Palmas, B Gamberi, R Zambello, MT Petrucci, P Corradini, M Cavo, M Boccadoro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading